Kaléo
Posted on: April 7, 2014
By: wordpress
With: Comments Off on Kaléo
Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products